In the News

NIH-developed AI algorithm matches potential volunteers to clinical trials

November 18, 2024 — Such an algorithm may save clinicians time and accelerate clinical enrollment and research.
NIH trial of rectal microbicide for HIV prevention begins in the United States

October 31, 2024 — Study will assess safety and acceptability of rectal douche for pre-exposure prophylaxis.
NIH clinical trial will test precision medicine treatments for myeloid cancers

October 23, 2024 — NCI has launched myeloMATCH, a precision medicine treatment trial for people with acute myeloid leukemia and myelodysplastic syndromes.
Drug Combo JAKs Up Immunotherapy in Two Clinical Trials

August 8, 2024 — Adding a JAK inhibitor to an immune checkpoint inhibitor shrank tumors in more than half of trial participants with lung cancer or lymphoma.
Vigorous exercise not linked to increased risk of adverse cardiac events in long QT syndrome

July 25, 2024 — NIH-supported study could lessen exercise restrictions for those with genetic heart condition.
Immunotherapy approach shows potential in some people with metastatic solid tumors

July 11, 2024 — NIH researchers achieved tumor shrinkage in three of seven patients with colorectal cancers.
Trial Establishes Preferred Treatment for Some People with Esophageal Cancer

July 9, 2024 — A large clinical trial looks to have settled a debate over how best to treat most people with locally advanced esophageal cancer, where the disease has spread just outside of the esophagus but not to other parts of the body.
Experimental mRNA Vaccine Hints at Potential Against Glioblastoma

June 11, 2024 — A nanoparticle-based mRNA vaccine improved survival in dogs with brain cancer and induced rapid immune responses in a small study in humans with glioblastoma.
U.S. clinical trials begin for twice-yearly HIV prevention injection

June 4, 2024 — Studies will focus on priority populations underrepresented in HIV clinical research.
Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer

May 21, 2024 — Pembrolizumab (Keytruda) treatment after surgery helped people with clear-cell renal cell carcinoma live longer in a large trial—a first for this cancer.

This page last reviewed on January 17, 2025

Looking for U.S. government information and services?

Visit USA.gov